These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 24283718)

  • 21. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-1 signaling pathway in sepsis: Does it have a future?
    Chen R; Zhou L
    Clin Immunol; 2021 Aug; 229():108742. PubMed ID: 33905818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus.
    Matsuyama-Kato A; Murata S; Isezaki M; Kano R; Takasaki S; Ichii O; Konnai S; Ohashi K
    Virol J; 2012 May; 9():94. PubMed ID: 22612856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PD-1/PD-L1 pathway in human pathology.
    Saresella M; Rainone V; Al-Daghri NM; Clerici M; Trabattoni D
    Curr Mol Med; 2012 Mar; 12(3):259-67. PubMed ID: 22300137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.
    Wang H; Kaur G; Sankin AI; Chen F; Guan F; Zang X
    J Hematol Oncol; 2019 Jun; 12(1):59. PubMed ID: 31186046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 in disease.
    Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK; Park BB; Uhm J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1.
    Kythreotou A; Siddique A; Mauri FA; Bower M; Pinato DJ
    J Clin Pathol; 2018 Mar; 71(3):189-194. PubMed ID: 29097600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The targeting of immunosuppressive mechanisms in hematological malignancies.
    Andersen MH
    Leukemia; 2014 Sep; 28(9):1784-92. PubMed ID: 24691076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
    Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
    Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1 as a potential target in cancer therapy.
    McDermott DF; Atkins MB
    Cancer Med; 2013 Oct; 2(5):662-73. PubMed ID: 24403232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of B-cell activation and antibody production by triggering inhibitory signals via the PD-1/PD-ligand pathway.
    Buermann A; Römermann D; Baars W; Hundrieser J; Klempnauer J; Schwinzer R
    Xenotransplantation; 2016 Sep; 23(5):347-56. PubMed ID: 27613101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.